{
    "clinical_study": {
        "@rank": "55412", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "risperidone plus placebo"
            }, 
            {
                "arm_group_label": "aripiprazole 5mg", 
                "arm_group_type": "Experimental", 
                "description": "risperidone treatment plus aripiprazole 5mg/day"
            }, 
            {
                "arm_group_label": "aripiprazole 10mg", 
                "arm_group_type": "Experimental", 
                "description": "risperidone plus aripiprazole 10mg/day"
            }, 
            {
                "arm_group_label": "aripiprazole 20mg", 
                "arm_group_type": "Experimental", 
                "description": "risperidone plus aripiprazole 20mg/day"
            }
        ], 
        "brief_summary": {
            "textblock": "Hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents\n      and atypical antipsychotics such as risperidone. Recent studies have suggested that\n      aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics.\n      Thus, we conducted this study to evaluate the dose effects of adjunctive treatment with\n      aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with\n      risperidone."
        }, 
        "brief_title": "Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": [
                "Hyperprolactinemia", 
                "Schizophrenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. aged 18-45 years of and fulfilled Diagnostic and Statistical Manual of Mental\n             Disorders(DSM-IV )criteria (American Psychiatric Association, 1994) for\n             schizophrenia;\n\n          2. having a stable psychiatric condition, defined as taking the same dosage of\n             risperidone for at least 6 weeks;\n\n          3. being treated with risperidone monotherapy; and presence of hyperprolactinemia\n             associated with risperidone.\n\n        Exclusion Criteria:\n\n          1. any other major psychiatric disorder;\n\n          2. significant concurrent medical illnesses, organic brain disorder, history of\n             substance and alcohol abuse, and mental retardation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013232", 
            "org_study_id": "ARI201206"
        }, 
        "intervention": {
            "arm_group_label": [
                "aripiprazole 5mg", 
                "aripiprazole 10mg", 
                "aripiprazole 20mg"
            ], 
            "intervention_name": "Aripiprazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Risperidone", 
                "Aripiprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Risperidone;", 
            "Aripiprazole;", 
            "Hyperprolactinemia;", 
            "dose effects"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "email": "chenjx1110@163.com", 
                "last_name": "Jingxu Chen", 
                "phone": "86-13681394260"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "102208"
                }, 
                "name": "Beijing HuiLongGuan Hospital"
            }, 
            "investigator": {
                "last_name": "Jingxu Chen", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study", 
        "other_outcome": {
            "description": "assess the extrapyramidal symptoms", 
            "measure": "extrapyramidal symptoms", 
            "safety_issue": "Yes", 
            "time_frame": "baseline, 4 weeks, 8 weeks"
        }, 
        "overall_contact": {
            "email": "chenjx1110@163.com", 
            "last_name": "Jingxu Chen, master", 
            "phone": "86-13681394260"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in the levels of prolactin", 
            "measure": "Prolactin level", 
            "safety_issue": "Yes", 
            "time_frame": "baseline, 2 weeks, 4 weeks, 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013232"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing HuiLongGuan Hospital", 
            "investigator_full_name": "Jingxu Chen", 
            "investigator_title": "associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Change from baseline in PANSS score", 
            "measure": "PANSS (positive and negative syndrome scale) score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 8 weeks"
        }, 
        "source": "Beijing HuiLongGuan Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing HuiLongGuan Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}